IQ Consortium

Organization of pharmaceutical and biotechnology companies with a mission of advancing science and technology.

What is IQ?

The IQ Consortium is a not-for-profit organization of pharmaceutical and biotechnology companies with the mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community.

IQ News

IQ 2024 Distinguished Service Awardees Announced

The IQ Distinguished Service Award recognizes outstanding individuals who have demonstrated enduring and impactful commitment to IQ’s mission. These individuals have made significant contributions to advancing IQ initiatives and have been proud ambassadors of the consortium. This is the inaugural year for this award, and we are delighted to honor our first class of awardees: Timothy Curran, Olivier Dirat, Timothy Hart, Sebastian Haertter, James Mann, Thomas Monticello, David Tan, and Jean-Pierre Valentin.

IQ Public Call

IQ Issues a Call for a Volunteer with Expertise in Polymer Chemistry

Responses Due 15-JUL-2025

The biologics physicochemical in-use stability testing working group is focused on industry-wide topics regarding in-use compatibility studies. The working group consists of biopharmaceutical experts in the field from many different companies. The objective of this working group is to establish best practices for designing, performing and presenting these in-use stability studies. The group also identifies applicable regional regulatory requirements and provides guidance where no specific regulations exist. Using scientific rationale and expert knowledge, the group is developing key perspectives to address these issues. 
 
The working group is discussing potential challenges around materials of construction of medical consumables.